



For Immediate Release

SENEXIS FILES NEW PATENTS TO PROTECT NOVEL ALZHEIMER'S COMPOUNDS

Cambridge, UK, 13th November 2009 - Senexis Limited, a private drug development company announced today that it has filed two further patents to protect its latest generation of bioavailable and CNS-penetrant small-molecule compounds, as a potential disease-modifying treatment for Alzheimer's disease. The compounds are neuroinflammation inhibitors for the potential treatment of the later stages of Alzheimer's disease.

David Scopes, Senexis' Chief Scientific Officer, commented: "we believe that that these novel compounds inhibit the inappropriate inflammation of the brain that can be triggered by amyloid. We now look forward to being able to accelerate the development of these small molecule compounds towards the clinic."

The number of people with Alzheimer's disease is expected to double over the next two decades. Currently, five million people in the US alone are affected by the disease.

CONTACTS

Senexis

Mark Treherne, Chief Executive
+44 (0)7711 190 718

About Senexis

Senexis is a drug development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of Alzheimer's and Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Further information on Senexis can be found at www.senexis.com.